CTOs on the Move


 
Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.elicio.com
  • 451 D Street 5th Floor, Suite 501
    Boston, MA USA 02210
  • Phone: 857.209.0050

Executives

Name Title Contact Details

Funding

Elicio raised $30M on 03/29/2019
Elicio raised $73M on 02/17/2021

Similar Companies

Croda

Croda is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

K-LaB Technologies

K-LaB Technologies, Inc. is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meiogen Biotechnology Corporation

Meiogen Biotechnology Corporation is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prolong Pharmaceuticals

Prolong is dedicated to the global biotechnology market, and to developing relationships with companies worldwide for raw material supply, commercial development and marketing of its new wave of products - the Supergenerics.

Ankyra Therapeutics

Ankyra is developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response.